ARTV

Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing natural killer (NK) cell-based therapies for patients suffering from devastating autoimmune diseases and cancers. Its product candidates are derived from donor cells (allogeneic) rather than a patient's own cells (autologous) and are pre-manufactured, stored frozen and ready to ship to a patient's treatment location. Its lead product candidate, AlloNK, is being evaluated in combination with B-cell targeted monoclonal antibodies (mAbs) in patients with autoimmune diseases and cancers, such as systemic lupus erythematosus (SLE), lupus nephritis (LN), RA, PV, the ANCA-associated vasculitis subtypes GPA/MPA, and B-NHL. AlloNK is a non-genetically modified, cryopreserved NK cell therapy being evaluated in combination with B-cell targeted mAbs in an ongoing Phase I/Ib trial in SLE with or without LN and a basket investigator-initiated trial (IIT) in multiple autoimmune indications.

Wall Street analysts forecast ARTV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARTV is 16.50 USD with a low forecast of 10.00 USD and a high forecast of 23.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Artiva Biotherapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

Artiva Biotherapeutics Inc. EPS for the last quarter amounts to -0.88 USD, decreased -4.35 % YoY.

Artiva Biotherapeutics Inc (ARTV) has 89 emplpoyees as of January 09 2026.

Today ARTV has the market capitalization of 112.42M USD.